How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , TG Therapeutics (TGTX) , Energy Transfer (ET) , Gilead Sciences (GILD) , VBI Vaccines (VBIV) , Agile Therapeutics (AGRX) , Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK) .

NASDAQ:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TRIL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $18.44
▼
$18.44
50-Day Range: $17.50
▼
$18.44
52-Week Range: $5.80
▼
$20.96

Volume: 8 shs
Average Volume: 1.87 million shs
Market Capitalization: $1.94 billion

P/E Ratio: 29.74
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Trillium Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Trillium Therapeutics Stock (NASDAQ:TRIL)

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

Click for my No. 1 investment, all free of charge, click here.

TRIL Stock News Headlines

November 10, 2023 | businesswire.com

Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com

November 8, 2023 | benzinga.com

Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

July 31, 2023 | uk.finance.yahoo.com

The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period

April 26, 2023 | msn.com

WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'

April 4, 2023 | uk.finance.yahoo.com

Leukemia Therapeutics Global Market Report 2023

March 28, 2023 | finance.yahoo.com

Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

October 19, 2022 | nz.finance.yahoo.com

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

September 14, 2022 | seekingalpha.com

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

September 12, 2022 | nz.finance.yahoo.com

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

August 17, 2022 | seekingalpha.com

Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed

June 22, 2022 | markets.businessinsider.com

10 Psychedelics CEOs To Pay Attention To In 2022

May 20, 2022 | edition.cnn.com

Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?

March 20, 2022 | nasdaq.com

3 Dividend Stocks That We'd Buy Without Any Hesitation

March 17, 2022 | stockhouse.com

Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders

February 17, 2022 | finanznachrichten.de

NeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, Ontario

December 14, 2021 | au.finance.yahoo.com

CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.com

December 14, 2021 | law360.com

3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals Buy

October 25, 2021 | finance.yahoo.com

Is Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?

October 16, 2021 | msn.com

2 Top Healthcare Stocks That Could Be Bought Out in 2022

October 13, 2021 | msn.com

BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14

September 22, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm

September 11, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRIL

September 9, 2021 | benzinga.com

Moore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law Firm

September 7, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing Investigations

September 4, 2021 | finance.yahoo.com

Why Investors Should Love Pfizer's Acquisition of Trillium

See More Headlines

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/18/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TRIL
CUSIP: N/A
CIK: 1616212
Web: www.trilliumtherapeutics.com
Phone: (416) 595-0627
Fax: N/A
Employees: 33
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.62
Trailing P/E Ratio: 29.74
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,350,000.00
Net Margins: N/A
Pretax Margin: -113,720.92%
Return on Equity: -23.31%
Return on Assets: -18.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.82
Quick Ratio: 19.82

Sales & Book Value

Annual Sales: $150,000.00
Price / Sales: 12,907.39
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.56 per share
Price / Book: 7.20

Miscellaneous

Outstanding Shares: 104,995,000
Free Float: 95,440,000
Market Cap: $1.94 billion
Optionable: Optionable
Beta: 2.08

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Jan Skvarka
President, Chief Executive Officer & Director
James T. Parsons
Chief Financial Officer
Robert A. Uger
Chief Scientific Officer
Kathleen Large
Senior Vice President-Clinical Operations
Ingmar Bruns
Chief Medical Officer

Key Competitors

View All Competitors

TRIL Stock Analysis - Frequently Asked Questions

How were Trillium Therapeutics' earnings last quarter?: Trillium Therapeutics Inc. (NASDAQ:TRIL) posted its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01.
What other stocks do shareholders of Trillium Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

This page (NASDAQ:TRIL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

About Trillium Therapeutics Stock (NASDAQ:TRIL)

TRIL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TRIL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info